At the news
? BULLISHIMPACT 8/10 8-K filed Feb 26, 2026 at 06:02 ET
Aurinia Pharmaceuticals reported strong financial results for 2025, with total revenue up 20% year-over-year to $283.1 million and net product sales of LUPKYNIS up 25% to $271.3 million. The company posted net income of $287.2 million, driven by a $173 million income tax benefit from releasing its deferred tax asset valuation allowance. For 2026, Aurinia guided for total revenue of $315-$325 million and LUPKYNIS sales of $305-$315 million.
- Total revenue for 2025 was $283.1 million, up 20% YoY
- Net product sales of LUPKYNIS were $271.3 million, up 25% YoY
- Net income was $287.2 million, up 4852% YoY due to $173 million tax benefit
- Cash flow from operations was $135.7 million, up 206% YoY
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access